JNJulius Nwobegahay

Julius Nwobegahay

*This is an algorithmically generated author record based on publicly available information.

Julius Nwobegahay has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adherence to Antiretroviral Therapy and Associated Factors Among People Living With HIV at the Yaounde Military Hospital, Cameroon: A Cross‐Sectional Study

    by Ethel S. Shang, Clovis Nkoke, Julius Nwobegahay, Charles Njumkeng, Betrand A. Tambe

    Background: Adherence to antiretroviral therapy (ART) is an essential component in the global response to HIV/AIDS. Despite increased access to ART in Cameroon, maintaining adherence to ART remains a significant challenge, jeopardising progress toward the global 95‐95‐95 HIV treatment targets. Objectives: To assess the level of adherence to ART and associated factors among people living with HIV at Yaounde Military Hospital in Cameroon. Methods: A cross‐sectional study was conducted from January to June 2025 among people living with HIV (PLHIV) aged 10 years and above receiving ART at the Yaounde Military Hospital. A simple random sampling technique was employed, whereby all eligible participants presenting for ART refill during the study period were invited to participate. A total of 356 PLHIV were interviewed using a structured questionnaire. Adherence to ART was measured using pill count and viral suppression. Descriptive statistics summarised demographic and clinical variables, Chi‐square tests assessed associations between categorical variables, and logistic regression identified factors associated with adherence. Statistical significance was set at p < 0.05. Results: The mean age of participants was 46.5 ± 15.1 years, ranging from 10 to 84 years, and the mean duration on ART was 9.4 ± 5.8 years, ranging from 0 to 24 years. An overall adherence rate, measured by pill count, was 86.0% (95% CI: 82.35–89.57), while out of 356 participants, 344 (96.6%; 95% CI: 94.7–98.3) were virally suppressed. Factors significantly associated with adherence included smoking (AOR = 5.27, 95% CI = 1.72–16.13, p = 0.004), male gender (AOR = 2.8, 95% CI = 1.12–7.31, p = 0.027) and ART adverse effects (AOR = 0.35, 95% CI = 0.14–0.87, p = 0.023). Conclusion: ART adherence in this study fell below the UNAIDS optimal target of ≥ 95%. Factors such as smoking, male gender and ART adverse effects significantly influence adherence. Targeted interventions addressing these barriers are essential to optimise adherence and sustain progress toward the 95‐95‐95 HIV treatment targets in Cameroon.

  • Open Access

    Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: Evidence from a cohort analysis in Cameroon

    by Yagai Bouba, Aude Christelle Ka’E, Davy-Hyacinthe Anguechia Gouissi, Cynthia Ayafor, Dominik Tameza Guebiapsi, Samuel Martin Sosso, Rachel Simo Kamgaing, Suzie Ndiang Tetang, Suzane Essamba, Nelly Kamgaing, et al.

    Achieving and maintaining viral suppression (VS) in pediatric populations remain suboptimal in low- and middle-income countries (LMICs), calling for the optimized management approaches. We compared the rate of confirmed virological failure (cVF) and associated factors among virally non-suppressed (VnS) children and adolescents after enhanced adherence counseling (EAC) on dolutegravir-based versus other regimens. A multicentre and prospective cohort study was conducted among ART-experienced children (P = .026. According to ART-regimen, cVF rate was 29.3% in those receiving TDF/3TC/DTG versus 43.5% for ABC/3TC + ATV/r/LPV/r and 25.6% for ABC/3TC + DTG, P = .007. Regarding anchor-drugs, cVF with DTG, EFV and ATV/r/LPV/r was 28.1%, 48.4% and 49.2%, respectively, P = .007. Interestingly, 13.2% of participants with VS had detectable low-level viremia (400–999 copies/mL), with 5.8%, 7.7% and 12.9% being observed in those receiving DTG, ATV/r/LPV/r, and EFV/NVP-based regimen, respectively, P = .013. Only anchor-drug was found to be a predictor of cVF. Compared to those receiving DTG-based regimens, ART based on ATV/LPV/r (aOR [95% CI]: 0.298 [0.132–0.72], P = .004) or EFV/NVP (aOR [95% CI]: 0.401 [0.163–0.983], P = .046) was significantly less likely to achieve VS. About 40% of Cameroonian children/adolescents with VnS experience cVF, which is indicative that EAC significantly contributes to viral re-suppression (60%), especially with DTG-based regimens. Thus, implementing a strategy that couples DTG-transition with EAC-interventions would contribute substantially to efforts in eliminating pediatric AIDS in LMICs.


  • Open Access

    Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study

    by Joseph Fokam, Yagai Bouba, Rogers Awoh Ajeh, Dominik Tameza Guebiapsi, Suzane Essamba, Albert Franck Zeh Meka, Ebiama Lifanda, Rose Armelle Ada, Liman Yakouba, Nancy Barbara Mbengono, et al.

    Mortality in children accounts for 15% of all AIDS-related deaths globally, with a higher burden among Cameroonian children (25%), likely driven by poor virological response. We sought to evaluate viral suppression (VS) and its determinants in a nationally representative paediatric and young adult population receiving antiretroviral therapy (ART). A cross-sectional and multicentric study was conducted among Cameroonian children (p < 0.001. VS was 85.1% on a DTG-based regimen versus 80.0% on efavirenz/nevirapine and 65.6% on lopinavir/ritonavir or atazanavir/ritonavir. VS was higher in females versus males (85.8% versus 78.2%, p < 0.001). The VS rate remained stable around 85% at 12 and 24 months but dropped to about 80% at 36 months after ART initiation, p < 0.009. Independent predictors of non-VS were younger age, longer ART duration (>36 months), backbone drug (non-TDF/3TC) and anchor drug (non-DTG based). In this Cameroonian paediatric population with varying levels of transition to DTG, overall VS remains below the 95% targets. Predictors of non-VS are younger age, non-TDF/3TC- and non-DTG-based regimens. Thus, efforts toward eliminating paediatric AIDS should prioritise the transition to a DTG-based regimen in this new ART era.


  • Open Access

    Evidence On Viral Suppression Supports Scaling-Up Transition To Dolutegravir-Based Regimens In Pediatric Populations In Cameroon: A Multicentre Baseline Assessment For The Cipher-Adola Study

    by Joseph Fokam, Yagai Bouba, Rogers Awoh Ajeh, Dominik Tameza Guebiapsi, Suzane Essamba, Albert Franck Zeh Meka, Ebiama Lifanda, Rose Armelle Ada, Yakouba Liman, Nancy Barbara Mbengono, et al.

    Mortality in children accounts for 15% of all AIDS-related deaths globally, with a higher burden among Cameroonian children (25%), likely due to poor virological response. We sought to evaluate viral suppression (VS) and its determinants in a nationally representative paediatric and young adult population receiving antiretroviral therapy (ART). A cross-sectional and multicentric study was conducted among Cameroonian children (

  • Low Prevalence and Risk Factors Related to HIV-1 Mother to Child Transmission under Option B+ Program at 3 Referral Military and Public Hospitals in Cameroon

    by Sabine Aimée Touangnou-Chamda, Maurice Boda, Arnaud Franck Elang, Donatien Serge Mbaga, Eric Simo, Sebastien Kenmoe, Justin Olivier Essindi, Chris André Mbongue Mikangue, Alexandra Emmanuelle Membangbi, Aicha Ngoutane, et al.


  • Open Access

    Clinical presentation of COVID-19 at the time of testing and factors associated with pre-symptomatic cases in Cameroon

    by Tejiokem Mathurin Cyrille, Sadeuh-Mba Serge, Tchatchueng Mbougwa Jules Brice, Tagnouokam Ngoupo Paul Alain, Ngondi Grace, Fokam Joseph, Hamadou Achta, Nke Gisèle, Nwobegahay Julius, Tongo Marcel, et al.


  • Open Access

    Seroprevalence and associated risk factors for Hepatitis B virus infection among barbers and their clients in two cities in Cameroon

    by Joël Brice Ngoupa, Patrick Achiangia Njukeng, Eric Ngoh Akwa, Michel Kengne, Ubald Tamoufe, Daniel Ter Goon, Julius Nwobegahay

    Background: Hepatitis B virus (HBV) infection is a serious public health problem in Africa and worldwide. Barbers are regularly in contact with the blood fluid of their clients, who could develop skin cuts and abrasions during shaving practices. There is scarcity of information about HBV among barbers in Cameroon. This study presents seroprevalence and associated risk factors for HBV infection among barbers and their clients in two cities (Yaounde and Douala) in Cameroon. Methods: Three millilitres of venous blood was collected into EDTA tubes from each of the 262 consenting participants. Plasma was obtained and transported to the Military Health Research Centre (CRESAR) for analysis. Sociodemographic data were collected using a structured questionnaire. The prevalence of Hepatitis B surface antigen (HBsAg) was determined by a rapid diagnostic test (DiaSpot HBsAg) and confirmed with an ELISA sandwich test. Data were analysed using SPSS, version 21. Results: Thirty-three participants tested positive, giving an overall prevalence of 12.6%. A seroprevalence of 15.0% and 10.6% was obtained for barbers and their clients respectively. In Yaounde, the frequency of HBsAg among barbers and their clients was 14.9% and 10.4% respectively, while in Douala it was 15.4% and 11.1% respectively. However, no statistically significant difference was observed in these groups. There was also no statistically significant association between the knowledge of the modes of HBV transmissions and HBV status. Conclusion: The present study reveals that the rate of HBsAg among the study population is high in Cameroon and most people are not still properly sensitised regarding prevention measures.


  • Open Access

    Seroprevalence and associated risk factors for Hepatitis B virus infection among barbers and their clients in two cities in Cameroon

    by Joël Brice Ngoupa, Patrick Achiangia Njukeng, Eric Ngoh Akwa, Michel Kengne, Ubald Tamoufe, Daniel Ter Goon, Julius Nwobegahay

    Background: Hepatitis B virus (HBV) infection is a serious public health problem in Africa and worldwide. Barbers are regularly in contact with the blood fluid of their clients, who could develop skin cuts and abrasions during shaving practices. There is scarcity of information about HBV among barbers in Cameroon. This study presents seroprevalence and associated risk factors for HBV infection among barbers and their clients in two cities (Yaounde and Douala) in Cameroon. Methods: Three millilitres of venous blood was collected into EDTA tubes from each of the 262 consenting participants. Plasma was obtained and transported to the Military Health Research Centre (CRESAR) for analysis. Sociodemographic data were collected using a structured questionnaire. The prevalence of Hepatitis B surface antigen (HBsAg) was determined by a rapid diagnostic test (DiaSpot HBsAg) and confirmed with an ELISA sandwich test. Data were analysed using SPSS, version 21. Results: Thirty-three participants tested positive, giving an overall prevalence of 12.6%. A seroprevalence of 15.0% and 10.6% was obtained for barbers and their clients respectively. In Yaounde, the frequency of HBsAg among barbers and their clients was 14.9% and 10.4% respectively, while in Douala it was 15.4% and 11.1% respectively. However, no statistically significant difference was observed in these groups. There was also no statistically significant association between the knowledge of the modes of HBV transmissions and HBV status. Conclusion: The present study reveals that the rate of HBsAg among the study population is high in Cameroon and most people are not still properly sensitised regarding prevention measures.


  • Open Access

    Comparison of in vitro pharmacodynamics equivalence of generic and branded antimicrobials

    by Akemfua Fualefac, Michel Kengne, Valentine Ndikum, Achiangia Patrick Njukeng, Ubald Tamoufe, Yaounde Metabiota Cameroon, Daniel Ter Goon, Cedric Mbakam Happi, Joel Ngoupa, Awung Nkeza, et al.

    There has been an enormous increase in the clinical use of generic drugs. However, this has not been accompanied by frequent and systematic evaluations of their therapeutic efficacy compared with branded products. Although essential to reduce health budget costs and to promote pharmaceutical competition, generic drugs remain a topic of intense controversy. Generics are usually intended to be interchangeable with branded products; however, there have been allegations that some have a lower therapeutic equivalence than their branded counterparts The main objective of this study was to compare the in vitro potency of generic and branded antibiotics on E. coli and S. aureus. A sample of generic and corresponding branded Ciprofloxacin, Ceftriazone, Gentamicin and Doxycycline were used to prepare antibiotic disk for Kirby-Bauer disk diffusion susceptibility antimicrobial assay on E. coli ATCC 25922 and S. aureus ATCC 25923. The inhibition zones were measured and relative potencies were calculated. Antimicrobial activity against S. aureus ATCC 25923 ranged from 92.50 to 100% for generic agents; and 96.89% to 100% for branded drugs. The potency range for E. coli ATCC 25922 were 86.61 to 104.35% for generics and 83.33 to 103.23% for branded antimicrobials. There was no significant difference between the potency of the generic and the branded antimicrobial agents on the bacterial strains in the study. Each generic antimicrobial agent presented relative potency that was within the 80-125% acceptable range. The in vitro pharmacodynamics potency of generic antimicrobials from health facilities and legal distributors are equivalent to their corresponding branded agents.

  • Open Access

    Hepatitis C virus seroprevalence among haemodialysis patients, sickle cell patients and blood donors at a tertiary hospital in Yaounde, Cameroon

    by Therese Ndomgue, Michel Kengne, Patrick Achiangia Njukeng, Valentine Ngum Ndze, Damien Nota Anong, Tracy Madimabi Masebe, Ubald Tamoufe, Anastasia Yenban Bongajum, Daniel Ter Goon, Julius Mbekem Nwobegahay

    Background: Hepatitis C virus (HCV) infection is a serious health care problem in haemodialysis patients, sickle cell patients and blood donation in Africa. However, there is a paucity of information about this in Cameroon. This study presents the prevalence of antibodies to HCV among haemodialysis patients, sickle cell patients and blood donors at the Yaounde University Teaching Hospital, Cameroon. Methods: A total of 113 participants were included in the study. Sociodemographic data were collected using a questionnaire. The prevalence of HCV antibodies was determined by a rapid diagnostic test (DiaSpot HCV One Step Hepatitis C Virus Test Strip) and data were analysed using Statistical Package for Social Science. Results: Of the 113 patients, 18 tested positive, giving an overall prevalence of 15.9%. 15.6% (12/77) males had HCV antibodies, while 16.7% (6/36) females tested positive with HCV antibodies. HCV positive rates of 26.3% (10/38), 8.6% (3/35) and 12.5% (5/40) for haemodialysis patients, sickle cell patients and blood donors, respectively, were recorded. However, no statistical significant differences were observed in these three groups (p = 0.089). Conclusion: The present study reveals that the rate of HCV antibodies among the study population is high and Cameroon could be a highly endemic society for HCV infection.